Literature DB >> 23872151

MicroRNA-340 suppresses osteosarcoma tumor growth and metastasis by directly targeting ROCK1.

Xin Zhou1, Min Wei, Wei Wang.   

Abstract

MicroRNAs (miRNAs) play key roles in cancer development and progression. In the present study, we investigated the role of miR-340 in the progression and metastasis of osteosarcoma (OS). Our results showed that miR-340 was frequently downregulated in OS tumors and cell lines. Overexpression of miR-340 in OS cell lines significantly inhibited cell proliferation, migration, and invasion in vitro, and tumor growth and metastasis in a xenograft mouse model. ROCK1 was identified as a target of miR-340, and ectopic expression of miR-340 downregulated ROCK1 by direct binding to its 3' untranslated region. siRNA-mediated silencing of ROCK1 phenocopied the effects of miR-340 overexpression, whereas restoration of ROCK1 in miR-340-overexpressing OS cells reversed the suppressive effects of miR-340. Together, these findings indicate that miR-340 acts as a tumor suppressor and its downregulation in tumor tissues may contribute to the progression and metastasis of OS through a mechanism involving ROCK1, suggesting miR-340 as a potential new diagnostic and therapeutic target for the treatment of OS.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Osteosarcoma; ROCK1; miR-340

Mesh:

Substances:

Year:  2013        PMID: 23872151     DOI: 10.1016/j.bbrc.2013.07.033

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  48 in total

1.  MicroRNA screening identifies circulating microRNAs as potential biomarkers for osteosarcoma.

Authors:  Hui Li; Kun Zhang; Li-Hong Liu; Yurong Ouyang; Hong-Bin Guo; Hanchong Zhang; Jie Bu; Tao Xiao
Journal:  Oncol Lett       Date:  2015-06-16       Impact factor: 2.967

Review 2.  Bone microenvironment signals in osteosarcoma development.

Authors:  Arantzazu Alfranca; Lucia Martinez-Cruzado; Juan Tornin; Ander Abarrategi; Teresa Amaral; Enrique de Alava; Pablo Menendez; Javier Garcia-Castro; Rene Rodriguez
Journal:  Cell Mol Life Sci       Date:  2015-05-03       Impact factor: 9.261

Review 3.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

4.  MicroRNA-150 upregulation reduces osteosarcoma cell invasion and metastasis by downregulating Ezrin.

Authors:  Ce Zhan; Cheng Li; Hao Zhang; Hao Tang; Fang Ji; Su-Chi Qiao; Wei-Dong Xu; Zhi-Wei Wang
Journal:  Oncol Lett       Date:  2016-08-25       Impact factor: 2.967

Review 5.  Epigenetic alterations in osteosarcoma: promising targets.

Authors:  Binghao Li; Zhaoming Ye
Journal:  Mol Biol Rep       Date:  2014-02-06       Impact factor: 2.316

6.  MicroRNA 340 is involved in UVB-induced dendrite formation through the regulation of RhoA expression in melanocytes.

Authors:  Qiang Jian; Qing An; Dongning Zhu; Kun Hui; Ying Liu; Sumin Chi; Chengxin Li
Journal:  Mol Cell Biol       Date:  2014-06-30       Impact factor: 4.272

7.  LncRNA MYCNOS facilitates proliferation and invasion in hepatocellular carcinoma by regulating miR-340.

Authors:  Junfeng Yu; Zhejian Ou; Yangyang Lei; Liuhua Chen; Qiao Su; Kunsong Zhang
Journal:  Hum Cell       Date:  2019-11-27       Impact factor: 4.174

8.  MicroRNA-144 inhibits the proliferation, apoptosis, invasion, and migration of osteosarcoma cell line F5M2.

Authors:  Shao-Qian Cui; Huan Wang
Journal:  Tumour Biol       Date:  2015-04-09

9.  Curcumin induces apoptotic cell death in human pancreatic cancer cells via the miR-340/XIAP signaling pathway.

Authors:  Deying Yang; Yutao Li; Deqin Zhao
Journal:  Oncol Lett       Date:  2017-06-06       Impact factor: 2.967

10.  MiR-145 inhibits osteosarcoma cells proliferation and invasion by targeting ROCK1.

Authors:  Enqi Li; Jinli Zhang; Tianxiang Yuan; Baotong Ma
Journal:  Tumour Biol       Date:  2014-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.